Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
about
A frequent kinase domain mutation that changes the interaction between PI3K and the membraneOncogenic mutations of PIK3CA in human cancersSomatic mutations in PI3Kalpha: structural basis for enzyme activation and drug designSrc, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma.Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapaIncreased signalling of EGFR and IGF1R, and deregulation of PTEN/PI3K/Akt pathway are related with trastuzumab resistance in HER2 breast carcinomas.PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.The favorable impact of PIK3CA mutations on survival: an analysis of 2587 patients with breast cancer.Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients.Structural effects of oncogenic PI3Kα mutations.Potential role of PI3K inhibitors in the treatment of breast cancer.Endocrine resistance in breast cancer: molecular pathways and rational development of targeted therapies.H1047R phosphatidylinositol 3-kinase mutant enhances HER2-mediated transformation by heregulin production and activation of HER3The anti-ErbB2 antibody H2-18 and the pan-PI3K inhibitor GDC-0941 effectively inhibit trastuzumab-resistant ErbB2-overexpressing breast cancer.PI3KCA mutations and/or PTEN loss in Her2-positive breast carcinomas treated with trastuzumab are not related to resistance to anti-Her2 therapy.The High Frequency of PIK3CA Mutations in Iranian Breast Cancer Patients.Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis.
P2860
Q27657679-78FAE6C1-2DCE-4234-9986-1B9585ED006DQ28284802-AD8FFF5D-AD9E-4CCC-A4F6-B9E5257CDBF3Q33653223-524D30EF-4E6C-44D1-BA14-9242022BF030Q34051933-6B7FCAA8-3469-400E-87FF-C18EB4B5212BQ34296114-B45EFEFF-3E4B-48EB-A346-301F99C5963BQ35889941-8DD5085F-5C55-409B-8E2F-C9D97744259CQ36978609-CEC43F6F-1DE7-4726-AFD7-E2E5C218950CQ37183710-7A18D117-AF96-42BE-923F-586E96C2A73AQ37589226-5BBBDB08-10CC-4AE3-BE31-423199D75B7FQ37769164-EB4A0C36-BF45-4D5B-918F-A73B16E42C10Q37783617-C9C7C7F1-D622-4204-AB4B-9FBE19E890A6Q37992693-0F7C75C6-4390-4999-A9EC-750AF5D43A62Q39687743-B15B1829-E119-42BE-A5C5-39C8BC0824F8Q41592949-BD763725-F547-448F-8CFD-B667A17AC9BAQ44585456-7766A616-2F19-4B63-B902-0B189F961A0FQ51295443-2EB496C2-A98F-427C-BD72-8A8D4F864763Q51807138-0D41F9E4-BBB7-496F-A869-7D9DF22F6C42
P2860
Exon 20 PIK3CA mutations decreases survival in aggressive (HER-2 positive) breast carcinomas.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Exon 20 PIK3CA mutations decre ...... 2 positive) breast carcinomas.
@en
Exon 20 PIK3CA mutations decreases survival in aggressive
@nl
type
label
Exon 20 PIK3CA mutations decre ...... 2 positive) breast carcinomas.
@en
Exon 20 PIK3CA mutations decreases survival in aggressive
@nl
prefLabel
Exon 20 PIK3CA mutations decre ...... 2 positive) breast carcinomas.
@en
Exon 20 PIK3CA mutations decreases survival in aggressive
@nl
P2093
P1433
P1476
Exon 20 PIK3CA mutations decre ...... -2 positive) breast carcinomas
@en
P2093
Agusti Barnadas
Carmen Alonso
Enrique Lerma
Gloria Peiro
Jaime Prat
Lluis Catasus
P2888
P304
P356
10.1007/S00428-008-0643-4
P577
2008-08-05T00:00:00Z
P6179
1052373208